PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8262865-2	1993	Tazobactam and clavulanate inhibit the enzyme, but beta-lactamase producers remained substantially less susceptible than non-producers to piperacillin/tazobactam and co-amoxiclav in disc tests.	Clavulanic Acid	15-26	beta-lactamase	Staphylococcus aureus	51-65	
9660985-5	1998	Clavulanic acid concentrations achievable in serum that changed over time allowed amoxicillin to act against the beta-lactamase-producing methicillin-resistant S. aureus to a similar extent as vancomycin.	Clavulanic Acid	0-15	beta-lactamase	Staphylococcus aureus	113-127	
8262865-6	1993	Thus, the MICs of piperacillin or amoxycillin with tazobactam or clavulanate were only two- to four-fold higher for beta-lactamase producers than non-producers at low inocula (10(4) cfu), but this differential increased to 6- to 16-fold at high inocula (10(6) cfu).	Clavulanic Acid	65-76	beta-lactamase	Staphylococcus aureus	116-130	
18975519-10	2008	This study demonstrated that cefpodoxime +clavulanic acid combination has more potent in vitro activity in comparison to amoxicillin+ clavulanic acid combination against beta-lactamase producing strains of Gram-positive and Gram-negative bacteria.	Clavulanic Acid	42-57	beta-lactamase	Staphylococcus aureus	170-184	
3266728-7	1988	Bactericidal activity was observed with two or four times the oxacillin MIC in eight strains tested at both temperatures, and the combination with clavulanic acid was bactericidal at higher than four times the MIC in five of the strains at 30 degrees C. Our results suggest that oxacillin intermediate MICs for staphylococcal isolates are due not only to beta-lactamase hyperproduction but also some other unidentified factor.	Clavulanic Acid	147-162	beta-lactamase	Staphylococcus aureus	355-369	
3892077-1	1985	BRL 25000 is a combination of a newly-developed beta-lactamase inhibitor clavulanic acid (CVA) and amoxicillin (AMPC) in the ratio of 1 to 2.	Clavulanic Acid	73-88	beta-lactamase	Staphylococcus aureus	48-62	
3892077-1	1985	BRL 25000 is a combination of a newly-developed beta-lactamase inhibitor clavulanic acid (CVA) and amoxicillin (AMPC) in the ratio of 1 to 2.	Clavulanic Acid	90-93	beta-lactamase	Staphylococcus aureus	48-62	
3266728-5	1988	For 6 of 10 beta-lactamase-positive strains, there was a greater-than-twofold-dilution reduction in oxacillin MICs with the addition of clavulanic acid or sulbactam.	Clavulanic Acid	136-151	beta-lactamase	Staphylococcus aureus	12-26	
3266728-6	1988	Of the four strains that became resistant with incubation at the lower temperature, a clavulanic acid effect was observed in three but only at 35 degrees C. The oxacillin MIC for one of the beta-lactamase-negative strains was also reduced with clavulanic acid; however, this strain was inhibited by 1 microgram of clavulanic acid per ml alone.	Clavulanic Acid	86-101	beta-lactamase	Staphylococcus aureus	190-204	
3266728-6	1988	Of the four strains that became resistant with incubation at the lower temperature, a clavulanic acid effect was observed in three but only at 35 degrees C. The oxacillin MIC for one of the beta-lactamase-negative strains was also reduced with clavulanic acid; however, this strain was inhibited by 1 microgram of clavulanic acid per ml alone.	Clavulanic Acid	244-259	beta-lactamase	Staphylococcus aureus	190-204	
3266728-6	1988	Of the four strains that became resistant with incubation at the lower temperature, a clavulanic acid effect was observed in three but only at 35 degrees C. The oxacillin MIC for one of the beta-lactamase-negative strains was also reduced with clavulanic acid; however, this strain was inhibited by 1 microgram of clavulanic acid per ml alone.	Clavulanic Acid	244-259	beta-lactamase	Staphylococcus aureus	190-204